EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Respiratorius AB (RESP) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Respiratorius AB SEK 0.68, price SEK 2.10, upside -67.6%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE

RA Thin data Sep 27, 2026

Respiratorius AB

RESP · ST

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 0.6800 · Strongly overvalued (−67.6%)
!Quality 37/100
!negative free cash flow
!Trails peers (2/6)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Respiratorius AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 131.60 kr 1.24 Fair Value kr 0.6800 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range kr 1.24 – kr 131.60 · fair‑value band kr 0.4505 – kr 0.8500 · the kr 2.10 price screens above the kr 0.6800 fair value. Dashed = 300-day average. As of Sep 27, 2026.

Follow Respiratorius in your weekly email

Every Wednesday you see whether Respiratorius is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer.

Show more

Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.

Stock analysis

Respiratorius AB (RESP) currently trades at kr 2.10, while our model-based Fair Value estimate is kr 0.6800, implying the stock looks roughly 208.8% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 87/100, which puts the evidence level at low.

Scenario range: kr 0.4505 (bear) to kr 0.8500 (bull), the price of kr 2.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Respiratorius AB reported revenue of 0 SEK in FY2025 versus 0 SEK in FY2023. Reported net income was −7.0M SEK in FY2025.

Key figures

Market cap 16.6M SEK (≈ $1.7M) · EPS (TTM) kr −0.7000 · Return on equity −24.9% · Return on assets (EBIT) −24.7% · Operating margin −60,065% · Revenue (TTM) 11.1K SEK · Free cash flow −7.8M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 69% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −68%, RESP screens richer than that median.

Fair Value models

Bear kr 0.4505 Fair Value kr 0.6800 Bull kr 0.8500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 1.94 kr 2.59 kr 3.87 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 1.94 kr 2.59 kr 3.87 51

Open the full fair value analysis →

Notify me when RESP reaches fair value

Put RESP on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 39 · Market factors (momentum, volatility) 31

Profitability 0
Margins and returns on capital today
Quality Growth 63
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 4
Calm price path (market factor)
Momentum 52
Price trend over the last 3–12 months (market factor)
52W Momentum 26
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: only 3 usable fiscal years, at least 4 required
not computed

RESP screens 209% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Respiratorius AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 39 · Below median
Fair Value upside −67.6% · Below median
Profitability
Return on assets −15.2% · Below median
Growth and dividend
Revenue growth 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.05× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $526.19 $578.81 +10%
Regeneron Pharmaceuticals, Inc REGN $788.04 $1,275 +62%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Respiratorius AB · Fair Value
kr 0.6800 −209%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Respiratorius AB Fair Value". https://www.fairvalue-calculator.com/stock/RESP

Frequently asked questions

Is Respiratorius AB (RESP) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of kr 0.6800 versus a price of kr 2.10, about −68% upside (overvalued).
What is the fair value of RESP?
Our model-based fair value for Respiratorius AB is kr 0.6800 (as of Sep 27, 2026), built from audited fundamentals. The current price: kr 2.10.
What is the quality score of RESP?
Respiratorius AB has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Respiratorius AB (RESP)?
Our model-based price target is the fair value of kr 0.6800 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario kr 0.4505, optimistic scenario kr 0.8500. It is a calculation from audited fundamentals, not an analyst target.
What is the Respiratorius AB stock forecast for 2026?
Our models put fair value at kr 0.6800, about −68% upside versus a price of kr 2.10 (overvalued). Cautious scenario kr 0.4505, optimistic scenario kr 0.8500. The calculation is refreshed regularly with new filings.
What is the revenue of Respiratorius AB (RESP)?
Respiratorius AB reported trailing-twelve-month revenue of about 11.1K SEK (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Respiratorius AB (RESP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Respiratorius AB it is kr 0.6800 per share (as of Sep 27, 2026), against a price of kr 2.10. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Respiratorius AB stock overvalued or undervalued in 2026?
As of Sep 27, 2026, RESP trades above its calculated fair value: price kr 2.10, fair value kr 0.6800, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RESP?
No. The price is what the market pays today (kr 2.10); the fair value is what the company's own numbers justify (kr 0.6800). For Respiratorius AB the two are kr 1.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Respiratorius AB worth?
The market values Respiratorius AB at about 16.6M SEK (market capitalisation, as of Sep 27, 2026). Per share that is kr 2.10; our models calculate a fair value of kr 0.6800 per share.
What do the bullish and bearish scenarios say about RESP?
Our models span a range for Respiratorius AB: cautious scenario kr 0.4505, base kr 0.6800, optimistic kr 0.8500 per share (as of Sep 27, 2026, price kr 2.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Respiratorius AB (RESP)?
Balance-sheet figures for Respiratorius AB (as of Sep 27, 2026): return on equity −24.9%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is RESP from its 52-week high?
Respiratorius AB trades at kr 2.10, about 37% below its 52-week high of kr 3.33 and 69% above the low of kr 1.24 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.6800 is for.
Which stocks are comparable to Respiratorius AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Respiratorius AB stock attractive at the current price?
The data as of Sep 27, 2026: price kr 2.10, calculated fair value kr 0.6800 (−68%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RESP calculated?
We run Respiratorius AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.6800, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Respiratorius AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Respiratorius AB (RESP)?
The closing price on Sep 25, 2026 was kr 2.10. Our model-based fair value is kr 0.6800, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Respiratorius AB right now?
The price sits above even our optimistic bull case (kr 0.8500). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.4505 to kr 0.8500) leaves room in how you read the outcome.

Key figures of Respiratorius AB

How large is the market capitalisation of Respiratorius AB (RESP)?
The market capitalisation of Respiratorius AB is 16.6M SEK (≈ $1.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Respiratorius AB (RESP)?
Earnings per share at Respiratorius AB are kr −0.7000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Respiratorius AB (RESP)?
The return on equity (ROE) of Respiratorius AB is −24.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Respiratorius AB (RESP)?
On an EBIT basis the return on assets of Respiratorius AB is −24.7% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Respiratorius AB (RESP)?
The operating margin of Respiratorius AB is −60,065% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Respiratorius AB (RESP) generate?
The free cash flow of Respiratorius AB is −7.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Respiratorius AB in the live analysis

One click puts Respiratorius AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.